Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Verified diagnosis of primary sclerosing cholangitis (PSC) for at least 12 months, with or without inflammatory bowel disease (IBD).~* Serum alkaline phosphatase (ALP) ≥ 1.5 times ULN and with no \>15% fluctuation in the past 3 months.~* In subjects receiving treatment with ursodeoxycholic acid (UDCA), therapy must be stable for at least 3 months and at a dose not greater than 20 mg/kg/day.~* Subjects of childbearing potential must agree to use a medically acceptable method of contraceptive to prevent pregnancy in the subject and/or the partner for the duration of their participation in the trial up to 2 months after the last study drug dosing.~Exclusion Criteria:~* Presence of documented secondary sclerosing cholangitis or small duct PSC~* Bacterial cholangitis within 30 days prior to Screening~* Presence of percutaneous drain or endoscopic bile duct stent~* History of, or suspicion of cholangiocarcinoma.~* Prior liver transplantation, or currently listed for liver transplantation~* Presence of other concomitant liver diseases~* Moderate to Severe active IBD or flare in colitis activity within the last 3 months~* Any severe and/or untreated concomitant cardiovascular, renal, endocrine or psychiatric disorder~* Any active malignant disease (within 3 years), other than non-melanomatous skin cancer~* Human immunodeficiency virus (HIV) infection~* Existing or intended pregnancy, or breast feeding~* Has received medication from another clinical trial within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DUR-928 10 mg (Type: EXPERIMENTAL): 10 mg oral suspension
- DUR-928 50 mg (Type: EXPERIMENTAL): 50 mg oral suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).